Development of AE147 Peptide-Conjugated Nanocarriers for Targeting uPAR-Overexpressing Cancer Cells

References

• World Health Organization. Latest global cancer data: cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018. International agency for research on cancer. Geneva: World Health Organization; 2018.
   Google Scholar
• Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006;12(8):895–904. doi:10.1038/nm1469
   PubMed Web of Science ®Google Scholar
• Geho DH, Bandle RW, Clair T, Liotta LA. Physiological mechanisms of tumor-cell invasion and migration. Physiology. 2005;20(3):194–200. doi:10.1152/physiol.00009.2005
   PubMedGoogle Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70. doi:10.1016/S0092-8674(00)81683-9
   PubMed Web of Science ®Google Scholar
• Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer. 2004;4(6):448–456. doi:10.1038/nrc1370
   PubMed Web of Science ®Google Scholar
• Hynes RO. Metastatic potential: generic predisposition of the primary tumor or rare, metastatic variants—or both? Cell. 2003;113(7):821–823. doi:10.1016/S0092-8674(03)00468-9
   PubMedGoogle Scholar
• Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006;25(1):9–34.
   PubMed Web of Science ®Google Scholar
• Montuori N, Pesapane A, Rossi FW, et al. Urokinase type plasminogen activator receptor (uPAR) as a new therapeutic target in cancer. Translat Med. 2016;15:15.
   Google Scholar
• Llinas P, Helene Le Du M, Gårdsvoll H, et al. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. EMBO J. 2005;24(9):1655–1663. doi:10.1038/sj.emboj.7600635
   PubMedGoogle Scholar
• Wang M, Miller AD, Thanou M. Effect of surface charge and ligand organization on the specific cell-uptake of uPAR-targeted nanoparticles. J Drug Target. 2013;21(7):684–692. doi:10.3109/1061186X.2013.805336
   PubMed Web of Science ®Google Scholar
• Mekkawy AH, Pourgholami MH, Morris DL. Involvement of urokinase-type plasminogen activator system in cancer: an overview. Med Res Rev. 2014;34(5):918–956.
   PubMed Web of Science ®Google Scholar
• Jo M, Lester RD, Montel V, Eastman B, Takimoto S, Gonias SL. Reversibility of epithelial-mesenchymal transition (EMT) induced in breast cancer cells by activation of urokinase receptor-dependent cell signaling*. J Biol Chem. 2009;284(34):22825–22833. doi:10.1074/jbc.M109.023960
   PubMed Web of Science ®Google Scholar
• Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev. 2008;34(2):122–136. doi:10.1016/j.ctrv.2007.10.005
   PubMed Web of Science ®Google Scholar
• Magdolen V, Rettenberger P, Koppitz M, et al. Systematic mutational analysis of the receptor‐binding region of the human urokinase‐type plasminogen activator. Eur J Biochem. 1996;237(3):743–751. doi:10.1111/j.1432-1033.1996.0743p.x
   PubMedGoogle Scholar
• Ploug M. Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site. Biochemistry. 1998;37(47):16494–16505.
   PubMedGoogle Scholar
• Li D, Liu S, Shan H, Conti P, Li Z. Urokinase plasminogen activator receptor (uPAR) Targeted nuclear imaging and radionuclide therapy. Rev Theranostics. 2013;3(7):507–515. doi:10.7150/thno.5557
   PubMedGoogle Scholar
• Li Santi A, Napolitano F, Montuori N, Ragno P. The urokinase receptor: a multifunctional receptor in cancer cell biology. therapeutic implications. Int J Mol Sci. 2021;22:8. doi:10.3390/ijms22084111
   Google Scholar
• LeBeau AM, Duriseti S, Murphy ST, et al. Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer. Cancer Res. 2013;73(7):2070–2081. doi:10.1158/0008-5472.CAN-12-3526
   PubMed Web of Science ®Google Scholar
• Yuan C, Guo Z, Yu S, Jiang L, Huang M. Development of inhibitors for uPAR: blocking the interaction of uPAR with its partners. Drug Discov Today. 2021;26(4):1076–1085. doi:10.1016/j.drudis.2021.01.016
   PubMedGoogle Scholar
• Sadzuka Y, Sugiyama I, Tsuruda T, Sonobe T. Characterization and cytotoxicity of mixed polyethyleneglycol modified liposomes containing doxorubicin. Int J Pharm. 2006;312(1–2):83–89. doi:10.1016/j.ijpharm.2005.12.043
   PubMed Web of Science ®Google Scholar
• Hua S, Wu SY. The use of lipid-based nanocarriers for targeted pain therapies. Front Pharmacol. 2013;4:143. doi:10.3389/fphar.2013.00143
   PubMed Web of Science ®Google Scholar
• Patil Y, Amitay Y, Ohana P, Shmeeda H, Gabizon A. Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: intracellular activation and enhanced cytotoxicity. J Controlled Release. 2016;225:87–95. doi:10.1016/j.jconrel.2016.01.039
   PubMed Web of Science ®Google Scholar
• Nogueira E, Gomes AC, Preto A, Cavaco-Paulo A. Design of liposomal formulations for cell targeting. Colloids Surf B Biointerfaces. 2015;136:514–526. doi:10.1016/j.colsurfb.2015.09.034
   PubMed Web of Science ®Google Scholar
• Muthu MS, Kulkarni SA, Xiong J, Feng -S-S. Vitamin E TPGS coated liposomes enhanced cellular uptake and cytotoxicity of docetaxel in brain cancer cells. Int J Pharm. 2011;421(2):332–340. doi:10.1016/j.ijpharm.2011.09.045
   PubMed Web of Science ®Google Scholar
• Singh S. Liposome encapsulation of doxorubicin and celecoxib in combination inhibits progression of human skin cancer cells. Int J Nanomedicine. 2018;13:11. doi:10.2147/IJN.S124701
   PubMedGoogle Scholar
• Metselaar JM, Storm G. Liposomes in the treatment of inflammatory disorders. Expert Opin Drug Deliv. 2005;2(3):465–476. doi:10.1517/17425247.2.3.465
   PubMedGoogle Scholar
• Hamidi M, Azadi A, Rafiei P. Pharmacokinetic consequences of pegylation. Drug Deliv. 2006;13(6):399–409. doi:10.1080/10717540600814402
   PubMed Web of Science ®Google Scholar
• Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet. 2003;42(5):419–436. doi:10.2165/00003088-200342050-00002
   PubMed Web of Science ®Google Scholar
• Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Advances and challenges of liposome assisted drug delivery. Front Pharmacol. 2015;6:286. doi:10.3389/fphar.2015.00286
   PubMed Web of Science ®Google Scholar
• Sahoo SK, Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov Today. 2003;8(24):1112–1120. doi:10.1016/S1359-6446(03)02903-9
   PubMed Web of Science ®Google Scholar
• Monteiro N, Martins A, Reis RL, Neves NM. Liposomes in tissue engineering and regenerative medicine. J R Soc Interface. 2014;11(101):20140459. doi:10.1098/rsif.2014.0459
   PubMed Web of Science ®Google Scholar
• Wu J, Liu Q, Lee RJ. A folate receptor-targeted liposomal formulation for paclitaxel. Int J Pharm. 2006;316(1–2):148–153. doi:10.1016/j.ijpharm.2006.02.027
   PubMedGoogle Scholar
• Wang B, Cao Z. Acid-catalyzed reactions of twisted amides in water solution: competition between hydration and hydrolysis. Chemistry. 2011;17(42):11919–11929. doi:10.1002/chem.201101274
   PubMedGoogle Scholar
• Kemnitz CR, Loewen MJ. “Amide resonance” correlates with a breadth of C−N rotation barriers. J Am Chem Soc. 2007;129(9):2521–2528. doi:10.1021/ja0663024
   PubMedGoogle Scholar
• Mujika JI, Mercero JM, Lopez X. Water-promoted hydrolysis of a highly twisted amide: rate acceleration caused by the twist of the amide bond. J Am Chem Soc. 2005;127(12):4445–4453. doi:10.1021/ja044873v
   PubMedGoogle Scholar
• Mustjoki S, Sidenius N, Sier CFM, et al. Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy. Cancer Res. 2000;60(24):7126.
   PubMedGoogle Scholar
• Llinas P, Hélène Le Du M, Gårdsvoll H. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. EMBO J. 2005;24(9):1655–1663.
   PubMedGoogle Scholar
• Saedi H. Intercalated polyamide-imide nanocomposite with montmorillonite. Am J Polymer Sci. 2015;5(2):47–53.
   Google Scholar
• Zhang Q, Zhao J, Hu H, et al. Construction and in vitro and in vivo evaluation of folic acid-modified nanostructured lipid carriers loaded with paclitaxel and chlorin e6. Int J Pharm. 2019;569:118595. doi:10.1016/j.ijpharm.2019.118595
   PubMedGoogle Scholar
• Qu M-H, Zeng R-F, Fang S, Dai Q-S, Li H-P, Long J-T. Liposome-based co-delivery of siRNA and docetaxel for the synergistic treatment of lung cancer. Int J Pharm. 2014;474(1–2):112–122. doi:10.1016/j.ijpharm.2014.08.019
   PubMedGoogle Scholar
• Immordino ML, Brusa P, Arpicco S, Stella B, Dosio F, Cattel L. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. J Controlled Release. 2003;91(3):417–429. doi:10.1016/S0168-3659(03)00271-2
   PubMed Web of Science ®Google Scholar
• Yang -Z-Z, Li J-Q, Wang -Z-Z, Dong D-W, Qi X-R. Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas. Biomaterials. 2014;35(19):5226–5239. doi:10.1016/j.biomaterials.2014.03.017
   PubMed Web of Science ®Google Scholar
• Rautela A, Rani J, Debnath M. Green synthesis of silver nanoparticles from Tectona grandis seeds extract: characterization and mechanism of antimicrobial action on different microorganisms. J Analytical Sci Tech. 2019;10(1):5. doi:10.1186/s40543-018-0163-z
   Web of Science ®Google Scholar
• Lim C, Moon J, Sim T, et al. Cyclic RGD-conjugated Pluronic® blending system for active, targeted drug delivery. Int J Nanomedicine. 2018;13:4627. doi:10.2147/IJN.S171794
   PubMed Web of Science ®Google Scholar
• Chang M, Lu S, Zhang F, et al. RGD-modified pH-sensitive liposomes for docetaxel tumor targeting. Colloids Surf B Biointerfaces. 2015;129:175–182. doi:10.1016/j.colsurfb.2015.03.046
   PubMed Web of Science ®Google Scholar
• Lim C, Kang JK, Won WR, et al. Co-delivery of D-(KLAKLAK) 2 peptide and chlorin e6 using a liposomal complex for synergistic cancer therapy. Pharmaceutics. 2019;11(6):293. doi:10.3390/pharmaceutics11060293
   PubMedGoogle Scholar
• Nguyen ST, Nguyen HT-L, Truong KD. Comparative cytotoxic effects of methanol, ethanol and DMSO on human cancer cell lines. Biomed Res Therapy. 2020;7(7):3855–3859. doi:10.15419/bmrat.v7i7.614
   Web of Science ®Google Scholar
• Wang J-L, Liu Y-L, Li Y, et al. EphA2 targeted doxorubicin stealth liposomes as a therapy system for choroidal neovascularization in rats. Invest Ophthalmol Vis Sci. 2012;53(11):7348–7357. doi:10.1167/iovs.12-9955
   PubMed Web of Science ®Google Scholar
• Zhang N, Li C, Zhou D, et al. Cyclic RGD functionalized liposomes encapsulating urokinase for thrombolysis. Acta Biomaterialia. 2018;70:227–236. doi:10.1016/j.actbio.2018.01.038
   PubMed Web of Science ®Google Scholar
• Sharpe M, Easthope SE, Keating GM, Lamb HM. Polyethylene glycol-liposomal doxorubicin. Drugs. 2002;62(14):2089–2126. doi:10.2165/00003495-200262140-00012
   PubMedGoogle Scholar
• Hammond N. Retraction: the next generation cell-penetrating peptide and carbon dot conjugated nano-liposome for transdermal delivery of curcumin. Biomaterials Sci. 2018;7(1):442. doi:10.1039/C8BM90064G
   PubMedGoogle Scholar
• Wang Y, Su W, Li Q, et al. Preparation and evaluation of lidocaine hydrochloride-loaded TAT-conjugated polymeric liposomes for transdermal delivery. Int J Pharm. 2013;441(1–2):748–756. doi:10.1016/j.ijpharm.2012.10.019
   PubMedGoogle Scholar
• Gårdsvoll H, Jacobsen B, Kriegbaum MC, et al. Conformational regulation of urokinase receptor function: IMPACT OF RECEPTOR OCCUPANCY AND EPITOPE-MAPPED MONOCLONAL ANTIBODIES ON LAMELLIPODIA INDUCTION. J Biol Chem. 2011;286(38):33544–33556. doi:10.1074/jbc.M111.220087
   PubMedGoogle Scholar
• Mekkawy AH, Morris DL, Pourgholami MH. Urokinase plasminogen activator system as a potential target for cancer therapy. Future Oncol. 2009;5(9):1487–1499. doi:10.2217/fon.09.108
   PubMed Web of Science ®Google Scholar
• Zhang Y, Kenny HA, Swindell EP, et al. Urokinase plasminogen activator system–targeted delivery of nanobins as a novel ovarian cancer therapy. Mol Cancer Ther. 2013;12(12):2628–2639. doi:10.1158/1535-7163.MCT-13-0204
   PubMedGoogle Scholar
• Bifulco K, Longanesi-Cattani I, Liguori E, et al. A Urokinase receptor–derived peptide inhibiting VEGF-dependent directional migration and vascular sprouting. Mol Cancer Ther. 2013;12(10):1981–1993. doi:10.1158/1535-7163.MCT-13-0077
   PubMedGoogle Scholar
• Mahmood N, Mihalcioiu C, Rabbani SA. Multifaceted role of the urokinase-type plasminogen activator (uPA) and its receptor (uPAR): diagnostic, prognostic, and therapeutic applications. Front Oncol. 2018;8:24. doi:10.3389/fonc.2018.00024
   PubMed Web of Science ®Google Scholar
• Su S-C, Lin C-W, Yang W-E, Fan W-L, Yang S-F. The urokinase-type plasminogen activator (uPA) system as a biomarker and therapeutic target in human malignancies. Expert Opin Ther Targets. 2016;20(5):551–566. doi:10.1517/14728222.2016.1113260
   PubMed Web of Science ®Google Scholar
• Li Y, Cozzi P. Targeting uPA/uPAR in prostate cancer. Cancer Treat Rev. 2007;33(6):521–527. doi:10.1016/j.ctrv.2007.06.003
   PubMedGoogle Scholar
• Martynenko IV, Kuznetsova VA, Orlova АO, et al. Chlorin e6–ZnSe/ZnS quantum dots based system as reagent for photodynamic therapy. Nanotechnology. 2015;26(5):055102. doi:10.1088/0957-4484/26/5/055102
   PubMedGoogle Scholar
• Du D, Wang K, Wen Y, Li Y, Li YY. Photodynamic graphene quantum dot: reduction condition regulated photoactivity and size dependent efficacy. ACS Appl Mater Interfaces. 2016;8(5):3287–3294. doi:10.1021/acsami.5b11154
   PubMed Web of Science ®Google Scholar
• Lim C, Sim T, Hoang NH, et al. A charge-reversible nanocarrier using PEG-PLL (-g-Ce6, DMA)-PLA for photodynamic therapy. Int J Nanomedicine. 2017;12:6185. doi:10.2147/IJN.S142912
   PubMed Web of Science ®Google Scholar
• He C, Hu Y, Yin L, Tang C, Yin C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials. 2010;31(13):3657–3666. doi:10.1016/j.biomaterials.2010.01.065
   PubMed Web of Science ®Google Scholar
• Zhu S, Hong M, Zhang L, Tang G, Jiang Y, Pei Y. PEGylated PAMAM dendrimer-doxorubicin conjugates: in vitro evaluation and in vivo tumor accumulation. Pharm Res. 2010;27(1):161–174. doi:10.1007/s11095-009-9992-1
   PubMed Web of Science ®Google Scholar